CoChat

Pulmonary Hypertension as a Risk Factor for Death in Patients with Sickle Cell Disease

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The prevalence of pulmonary hypertension in adults with sickle cell disease, the mechanism of its development, and its prospective prognostic significance are unknown. METHODS: We performed Doppler echocardiographic assessments of pulmonary-artery systolic pressure in 195 consecutive patients (82 men and 113 women; mean [+/-SD] age, 36+/-12 years). Pulmonary hypertension was prospectively defined as a tricuspid regurgitant jet velocity of at least 2.5 m per second. Patients were followed for a mean of 18 months, and data were censored at the time of death or loss to follow-up. RESULTS: Doppler-defined pulmonary hypertension occurred in 32 percent of patients. Multiple logistic-regression analysis, with the use of the dichotomous variable of a tricuspid regurgitant jet velocity of less than 2.5 m per second or 2.5 m per second or more, identified a self-reported history of cardiovascular or renal complications, increased systolic blood pressure, high lactate dehydrogenase levels (a marker of hemolysis), high levels of alkaline phosphatase, and low transferrin levels as significant independent correlates of pulmonary hypertension. The fetal hemoglobin level, white-cell count, and platelet count and the use of hydroxyurea therapy were unrelated to pulmonary hypertension. A tricuspid regurgitant jet velocity of at least 2.5 m per second, as compared with a velocity of less than 2.5 m per second, was strongly associated with an increased risk of death (rate ratio, 10.1; 95 percent confidence interval, 2.2 to 47.0; P<0.001) and remained so after adjustment for other possible risk factors in a proportional-hazards regression model. CONCLUSIONS: Pulmonary hypertension, diagnosed by Doppler echocardiography, is common in adults with sickle cell disease. It appears to be a complication of chronic hemolysis, is resistant to hydroxyurea therapy, and confers a high risk of death. Therapeutic trials targeting this population of patients are indicated.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa035477

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 44 references

Cited by

Items 401–500 of 999

Metadata

Authors
Gladwin, M. T., Sachdev, V., Jison, M. L., Shizukuda, Y., Plehn, J. F., Minter, K., Brown, B., Coles, W. A., Nichols, J. S., Ernst, I., Hunter, L. A., Blackwelder, W. C., Schechter, A. N., Rodgers, G. P., Castro, O., & Ognibene, F. P.
Affiliations
  • National Institutes of Health (US)
  • National Heart, Lung, and Blood Institute (US)
Venue
New England Journal of Medicine
Published
2004-02-26
Volume
350
Issue
9
Pages
886-895
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2148547093
Cited by
1,325
References
42
Citations by year
2026: 42 · 2025: 30 · 2024: 45 · 2023: 44 · 2022: 42 · 2021: 47 · 2020: 34 · 2019: 61 · 2018: 43 · 2017: 57 · 2016: 74 · 2015: 64 · 2014: 76 · 2013: 64 · 2012: 68
FWCI
35.46
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Howard (Howard University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
Keywords
pulmonary hypertension, sickle cell disease, mortality risk, tricuspid regurgitation velocity, Doppler echocardiography, chronic hemolysis, hydroxyurea therapy, risk factors, alkaline phosphatase, lactate dehydrogenase, transferrin, cardiovascular complications, renal complications
MeSH terms
Adult, Anemia, Sickle Cell, Antisickling Agents, Blood Pressure, Cause of Death, Drug Resistance, Female, Hemolysis, Humans, Hydroxyurea, Hypertension, Pulmonary, Male, Pulmonary Artery, Risk Factors, Tricuspid Valve Insufficiency, Echocardiography, Doppler, Prevalence, Survival Rate, Logistic Models, Ventricular Function

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.